Cerebrospinal Fluid Markers in Sporadic Creutzfeldt-Jakob Disease
暂无分享,去创建一个
A. Cagnin | G. Zanusso | S. Monaco | A. Galassi | A. Gajofatto | S. Ferrari | M. Fiorini | S. Richelli
[1] J. Chapman,et al. Tau and 14-3-3 of genetic and sporadic Creutzfeldt–Jakob disease patients in Israel , 2011, Journal of Neurology.
[2] W. Zhou,et al. Elevated Levels of Tau Protein in Cerebrospinal Fluid of Patients With Probable Creutzfeldt-Jakob Disease , 2010, The American journal of the medical sciences.
[3] A. Green,et al. The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt–Jakob disease in the UK: a 10-year review , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[4] H. Kretzschmar,et al. 14-3-3 CSF levels in sporadic Creutzfeldt–Jakob disease differ across molecular subtypes , 2009, Neurobiology of Aging.
[5] C. Begue,et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease , 2009, Brain : a journal of neurology.
[6] B. Hemmer,et al. EFNS guidelines on disease‐specific CSF investigations , 2009, European journal of neurology.
[7] A. Green,et al. The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt–Jakob disease , 2009, Neuroscience Letters.
[8] I. Santana,et al. Diagnostic value of CSF protein profile in a Portuguese population of sCJD patients , 2009, Journal of Neurology.
[9] R. Petersen,et al. Rapidly progressive neurodegenerative dementias. , 2009, Archives of neurology.
[10] B. Miller,et al. Rapidly Progressive Dementia , 2016, Continuum.
[11] K. Hess,et al. CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies , 2007, European journal of neurology.
[12] H. Monaco,et al. Detection of CSF 14-3-3 protein in Guillain–Barré syndrome , 2006, Neurology.
[13] K. Hess,et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease , 2006, Neurology.
[14] G. Zanusso,et al. Cerebral amyloidoses: molecular pathways and therapeutic challenges. , 2006, Current medicinal chemistry.
[15] K. Blennow,et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.
[16] G. Zanusso,et al. Molecular mechanisms of human prion diseases , 2005 .
[17] H. Monaco,et al. Phosphorylated 14-3-3ζ protein in the CSF of neuroleptic-treated patients , 2005, Neurology.
[18] Jennifer Farmer,et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease , 2005, Annals of neurology.
[19] P. Righetti,et al. Identification of Distinct N-terminal Truncated Forms of Prion Protein in Different Creutzfeldt-Jakob Disease Subtypes* , 2004, Journal of Biological Chemistry.
[20] R. Castellani,et al. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease , 2004, Neurology.
[21] J. Martín,et al. A prospective study of CSF markers in 250 patients with possible Creutzfeldt–Jakob disease , 2003, Journal of neurology, neurosurgery, and psychiatry.
[22] H. Vanderstichele,et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt–Jakob disease from other dementias , 2003, Molecular Psychiatry.
[23] J. Wiltfang,et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt–Jakob disease , 2002, Neurology.
[24] H. Budka,et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease , 2000, Neurology.
[25] J. Kornhuber,et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease , 1997, Neuroscience Letters.
[26] C. Gibbs,et al. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. , 1996, The New England journal of medicine.
[27] J Q Trojanowski,et al. Molecular basis of phenotypic variability in sporadc creudeldt‐jakob disease , 1996, Annals of neurology.